vs
Side-by-side financial comparison of PCB BANCORP (PCB) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.
Phathom Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($57.6M vs $29.2M, roughly 2.0× PCB BANCORP). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 11.3%). PCB BANCORP produced more free cash flow last quarter ($24.4M vs $-167.0M).
PCB Bank is an American community bank that focuses on the Korean-American community based in California and offers commercial banking services. It has branches in 8 states and is the third largest Korean American Bank after Bank of Hope and Hanmi Bank.
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
PCB vs PHAT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $29.2M | $57.6M |
| Net Profit | — | — |
| Gross Margin | — | 86.7% |
| Operating Margin | 45.0% | — |
| Net Margin | — | — |
| Revenue YoY | 11.3% | 94.1% |
| Net Profit YoY | — | 71.6% |
| EPS (diluted) | $0.65 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $29.2M | $57.6M | ||
| Q3 25 | $30.4M | $49.5M | ||
| Q2 25 | $29.3M | $39.5M | ||
| Q1 25 | $26.9M | $28.5M | ||
| Q4 24 | $26.2M | $29.7M | ||
| Q3 24 | $25.3M | $16.4M | ||
| Q2 24 | $24.2M | $7.3M | ||
| Q1 24 | $23.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | $11.4M | $-30.0M | ||
| Q2 25 | $9.1M | $-75.8M | ||
| Q1 25 | $7.7M | $-94.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $7.8M | $-85.6M | ||
| Q2 24 | $6.3M | $-91.4M | ||
| Q1 24 | $4.7M | — |
| Q4 25 | — | 86.7% | ||
| Q3 25 | — | 87.5% | ||
| Q2 25 | — | 87.2% | ||
| Q1 25 | — | 86.9% | ||
| Q4 24 | — | 87.1% | ||
| Q3 24 | — | 85.6% | ||
| Q2 24 | — | 81.2% | ||
| Q1 24 | — | — |
| Q4 25 | 45.0% | — | ||
| Q3 25 | 52.3% | -30.8% | ||
| Q2 25 | 43.3% | -151.7% | ||
| Q1 25 | 40.2% | -276.5% | ||
| Q4 24 | 39.3% | — | ||
| Q3 24 | 42.2% | -433.0% | ||
| Q2 24 | 36.3% | -1055.4% | ||
| Q1 24 | 27.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 37.5% | -60.5% | ||
| Q2 25 | 31.0% | -191.9% | ||
| Q1 25 | 28.8% | -330.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 30.8% | -523.3% | ||
| Q2 24 | 25.9% | -1248.6% | ||
| Q1 24 | 19.6% | — |
| Q4 25 | $0.65 | — | ||
| Q3 25 | $0.78 | $-0.41 | ||
| Q2 25 | $0.62 | $-1.05 | ||
| Q1 25 | $0.53 | $-1.31 | ||
| Q4 24 | $0.46 | — | ||
| Q3 24 | $0.52 | $-1.32 | ||
| Q2 24 | $0.43 | $-1.56 | ||
| Q1 24 | $0.33 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $207.1M | $130.0M |
| Total DebtLower is stronger | — | $209.1M |
| Stockholders' EquityBook value | $390.0M | $-438.2M |
| Total Assets | $3.3B | $259.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $207.1M | $130.0M | ||
| Q3 25 | $369.5M | $135.2M | ||
| Q2 25 | $263.6M | $149.6M | ||
| Q1 25 | $214.3M | $212.3M | ||
| Q4 24 | $198.8M | $297.3M | ||
| Q3 24 | $193.1M | $334.7M | ||
| Q2 24 | $177.6M | $276.2M | ||
| Q1 24 | $239.8M | — |
| Q4 25 | — | $209.1M | ||
| Q3 25 | — | $207.1M | ||
| Q2 25 | — | $205.1M | ||
| Q1 25 | — | $203.2M | ||
| Q4 24 | — | $201.4M | ||
| Q3 24 | — | $175.7M | ||
| Q2 24 | — | $174.4M | ||
| Q1 24 | — | — |
| Q4 25 | $390.0M | $-438.2M | ||
| Q3 25 | $384.5M | $-422.5M | ||
| Q2 25 | $376.5M | $-405.8M | ||
| Q1 25 | $370.9M | $-338.4M | ||
| Q4 24 | $363.8M | $-253.6M | ||
| Q3 24 | $362.3M | $-187.1M | ||
| Q2 24 | $353.5M | $-233.8M | ||
| Q1 24 | $350.0M | — |
| Q4 25 | $3.3B | $259.1M | ||
| Q3 25 | $3.4B | $240.3M | ||
| Q2 25 | $3.3B | $250.2M | ||
| Q1 25 | $3.2B | $294.2M | ||
| Q4 24 | $3.1B | $378.3M | ||
| Q3 24 | $2.9B | $387.0M | ||
| Q2 24 | $2.9B | $319.4M | ||
| Q1 24 | $2.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $26.6M | $-166.8M |
| Free Cash FlowOCF − Capex | $24.4M | $-167.0M |
| FCF MarginFCF / Revenue | 83.6% | -290.0% |
| Capex IntensityCapex / Revenue | 7.5% | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $46.0M | $-328.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $26.6M | $-166.8M | ||
| Q3 25 | $16.4M | $-14.1M | ||
| Q2 25 | $4.9M | $-62.7M | ||
| Q1 25 | $2.3M | $-84.9M | ||
| Q4 24 | $39.0M | $-266.8M | ||
| Q3 24 | $11.9M | $-63.6M | ||
| Q2 24 | $14.6M | $-70.7M | ||
| Q1 24 | $8.2M | — |
| Q4 25 | $24.4M | $-167.0M | ||
| Q3 25 | $16.2M | $-14.1M | ||
| Q2 25 | $3.8M | $-62.8M | ||
| Q1 25 | $1.6M | $-84.9M | ||
| Q4 24 | $34.9M | $-266.9M | ||
| Q3 24 | $11.9M | $-63.6M | ||
| Q2 24 | $12.8M | $-70.8M | ||
| Q1 24 | $6.0M | — |
| Q4 25 | 83.6% | -290.0% | ||
| Q3 25 | 53.2% | -28.6% | ||
| Q2 25 | 13.1% | -159.0% | ||
| Q1 25 | 6.0% | -297.9% | ||
| Q4 24 | 133.2% | -899.8% | ||
| Q3 24 | 46.8% | -389.0% | ||
| Q2 24 | 53.1% | -966.2% | ||
| Q1 24 | 25.2% | — |
| Q4 25 | 7.5% | 0.4% | ||
| Q3 25 | 0.8% | 0.1% | ||
| Q2 25 | 3.7% | 0.2% | ||
| Q1 25 | 2.8% | 0.1% | ||
| Q4 24 | 15.5% | 0.5% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 7.3% | 0.6% | ||
| Q1 24 | 9.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 2.33× | — | ||
| Q1 24 | 1.76× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
